公开(公告)号：US10696639B2

公开(公告)日：2020-06-30

申请号：US16466783

申请日：2017-12-01

申请人： Merck Sharp & Dohme Corp.

发明人： Tanweer Khan ,  Elizabeth Smith ,  Peter Williams ,  Catherine Wiscount ,  Brian McKittrick ,  John McCauley

IPC分类号： C07D233/88 ,  A61K31/4439 ,  A61K31/4168 ,  C07D401/12

摘要： The present invention is directed to compounds of Formula (I), pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

公开(公告)号：US09550786B2

公开(公告)日：2017-01-24

申请号：US14761170

申请日：2014-01-13

申请人： Merck Sharp & Dohme Corp.

发明人： Andrew Cooke ,  Scott D. Kuduk ,  Craig Stump ,  Peter Williams

IPC分类号： C07D487/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D487/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

摘要： The present invention is directed to 4-fluoropiperidine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

摘要翻译： 本发明涉及作为食欲素受体的拮抗剂的4-氟哌啶化合物，其可用于治疗或预防涉及食欲肽受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。

公开(公告)号：US20190337902A1

公开(公告)日：2019-11-07

申请号：US16466783

申请日：2017-12-01

申请人： Merck Sharp & Dohme Corp.

发明人： Tanweer Khan ,  Elizabeth Smith ,  Peter Williams ,  Catherine Wiscount ,  Brian McKittrick ,  John McCauley

IPC分类号： C07D233/88 ,  C07D401/12

摘要： The present invention is directed to compounds of Formula (I), pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.